The study was stopped prematurely after a median follow-up of 1.9 years (maximum follow-up of 5 years) because rosuvastatin therapy demonstrated a highly significant 44% reduction in cardiovascular events. 52 There were significant differences between rosuvastatin and placebo in the incidence of the individual components of the primary efficacy end point, including nonfatal myocardial infarction (hazard ratio [HR] 0.35, 95% confidence interval [CI] 0.22–0.58),
1
—
—